4.13
-0.22 (-5.06%)
| Previous Close | 4.35 |
| Open | 4.36 |
| Volume | 815,361 |
| Avg. Volume (3M) | 901,811 |
| Market Cap | 511,612,480 |
| Price / Sales | 6.36 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -197.64% |
| Operating Margin (TTM) | -123.58% |
| Diluted EPS (TTM) | -1.42 |
| Quarterly Revenue Growth (YOY) | 27.60% |
| Current Ratio (MRQ) | 4.46 |
| Operating Cash Flow (TTM) | -136.07 M |
| Levered Free Cash Flow (TTM) | -110.34 M |
| Return on Assets (TTM) | -27.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ADC Therapeutics SA | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 2.0 |
| Average | -0.88 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.58% |
| % Held by Institutions | 66.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 31 Dec 2025 | 15,666,731 |
| Tcg Crossover Management, Llc | 31 Dec 2025 | 11,390,175 |
| Prosight Management, Lp | 31 Dec 2025 | 8,477,338 |
| Orbimed Advisors Llc | 31 Dec 2025 | 5,822,854 |
| Eventide Asset Management, Llc | 31 Dec 2025 | 3,364,067 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | ADC Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 30 Jan 2026 | Announcement | $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium |
| 08 Jan 2026 | Announcement | ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates |
| 08 Jan 2026 | Announcement | ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 02 Jan 2026 | Announcement | ADC Therapeutics Announces New Employee Inducement Grant |
| 19 Dec 2025 | Announcement | Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |